Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate pancer: multicenter Phase IIb clinical trial
Jpn J Clin Oncol
.
2017 Mar 1;47(3):283.
doi: 10.1093/jjco/hyw177.
Authors
Hiroyoshi Suzuki
1
,
Yusuke Inoue
2
,
Hiroyuki Fujimoto
3
,
Junji Yonese
4
,
Kazunari Tanabe
5
,
Satoshi Fukasawa
6
,
Tomio Inoue
7
,
Shiro Saito
8
,
Munehisa Ueno
9
,
Akiharu Otaka
10
Affiliations
1
Department of Urology, Toho University Sakura Medical Center, Sakura.
2
Department of Diagnostic Radiology, Kitasato University School of Medicine, Sagamihara.
3
Department of Urology, National Cancer Center Hospital, Tokyo.
4
Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.
5
Department of Urology, Tokyo Women's Medical University, Tokyo.
6
Prostate Center and Division of Urology, Chiba Cancer Center, Chiba.
7
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama.
8
Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo.
9
Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka.
10
Clinical Development Department, Nihon Medi-Physics Co., Ltd., Tokyo, Japan.
PMID:
27920097
DOI:
10.1093/jjco/hyw177
No abstract available
Publication types
Published Erratum